There are currently 621 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California, Davis Medical Center, University of California, Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
NCT05358886
Recruiting
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome
Gender:
Male
Ages:
Between 18 years and 45 years
Trial Updated:
02/21/2024
Locations: UC Davis Health System, Sacramento, California
Conditions: Fragile X Syndrome
Register for Updates
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/21/2024
Locations: University of California, Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Advanced Solid Tumor
Register for Updates
A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome
NCT05163808
Recruiting
This is a 2-part study, with each part having a unique set of objectives for male adolescents aged 9 to < 18 years with fragile X syndrome (FXS). Part 1 is an open-label, single-dose, pharmacokinetics (PK) assessment of BPN14770 25 mg and 50 mg, while Part 2 is double-blind (DB) and randomized between two treatment groups (Study Drug and Placebo).
Gender:
Male
Ages:
Between 9 years and 18 years
Trial Updated:
02/21/2024
Locations: UC Davis, Sacramento, California
Conditions: Fragile X Syndrome
Register for Updates
Development and Testing of a Pediatric Cervical Spine Injury Risk Assessment Tool
NCT05049330
Recruiting
Cervical spine injuries (CSI) are serious, but rare events in children. Spinal precautions (rigid cervical collar and immobilization on a longboard) in the prehospital setting may be beneficial for children with CSI, but are poorly studied. In contrast, spinal precautions for pediatric trauma patients without CSI are common and may be associated with harm. Spinal precautions result in well-documented adverse physical and physiological sequelae. Of substantial concern is that the mere presence of... Read More
Gender:
All
Ages:
18 years and below
Trial Updated:
02/21/2024
Locations: Children's Hospital UC Davis Health, Sacramento, California
Conditions: Cervical Spine Injury
Register for Updates
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562
Recruiting
The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease. The goal of the study is to determine if Dostarlimab therapy alone is an effective... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/18/2024
Locations: GSK Investigational Site, Sacramento, California
Conditions: Neoplasms, Rectal
Register for Updates
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
NCT05509023
Recruiting
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Integrative Skin Science and Research, Sacramento, California
Conditions: Atopic Dermatitis
Register for Updates
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270
Recruiting
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
Gender:
All
Ages:
50 years and above
Trial Updated:
02/15/2024
Locations: Retinal Consultants Medical Group, Sacramento, California
Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Register for Updates
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
NCT02717156
Recruiting
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients with specific solid tumors. There will be four cohorts in this trial: Cohort A, phase II 2nd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. Cohort B, phase II 3rd lin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: UC Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
Register for Updates
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/09/2024
Locations: Direct Biologics Investigational Site, Sacramento, California
Conditions: Acute Respiratory Distress Syndrome, ARDS
Register for Updates
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
NCT05383209
Recruiting
A prospective, randomized, double-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to sham
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: EyePoint Investigative Site, Sacramento, California
Conditions: Nonproliferative Diabetic Retinopathy
Register for Updates
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
NCT05818085
Recruiting
This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.
Gender:
All
Ages:
Between 19 years and 69 years
Trial Updated:
02/08/2024
Locations: Center for Clinical Trials of Sacramento, Sacramento, California
Conditions: Gout
Register for Updates
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
NCT05690204
Recruiting
The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the appropriate dose regimen for future studies in adult subjects with gout, with or without tophi, and hyperuricemia refractory to SoC XOI therapy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/07/2024
Locations: California Site, Sacramento, California
Conditions: Gout
Register for Updates